Rilutek Related Published Studies
Well-designed clinical trials related to Rilutek (Riluzole)
Riluzole in Huntington's disease: a 3-year, randomized controlled study. [2007.09]
Placebo-controlled trial of riluzole in multiple system atrophy. [2006.10]
Prognostic factors for survival in amyotrophic lateral sclerosis patients treated with riluzole. [2005.03]
Efficacy screening trials of paroxetine, pentoxifylline, riluzole, pramipexole and venlafaxine in cocaine dependence. [2005.03]
Effect of riluzole on dyskinesia and duration of the on state in Parkinson disease patients: a double-blind, placebo-controlled pilot study. [2004.01]
A phase 1 trial of riluzole in spinal muscular atrophy. [2003.11]
Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). [2003.09]
A study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis. [2002.05]
Long-term safety of riluzole in amyotrophic lateral sclerosis. [2002.03]
A double-blind, placebo-controlled and longitudinal study of riluzole in early Parkinson's disease. [2002.03]
A double-blind, placebo-controlled randomized clinical trial of alpha-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. ALS riluzole-tocopherol Study Group. [2001.03]
The glutamate antagonist riluzole and its effects upon basal and stress-induced activity of the human hypothalamus-pituitary-adrenocortical system in elderly subjects. [2001]
Lack of efficacy of riluzole in the treatment of peripheral neuropathic pain conditions. [2000.10.10]
Effect of riluzole on acute pain and hyperalgesia in humans. [1999.05]
Riluzole has no acute effect on motor unit parameters in ALS. [1998.10]
An analysis of extended survival in patients with amyotrophic lateral sclerosis treated with riluzole. [1998.04]
Single- and multiple-dose pharmacokinetics of riluzole in white subjects. [1997.09]
Clinical trials of riluzole in patients with ALS. ALS/Riluzole Study Group-II. [1996.10]
Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. [1996.05.25]
Effects of the novel neuroprotective agent, riluzole, on human brain function and behavior: II. Double-blind, placebo-controlled EEG mapping and psychometric studies under hypoxia. [1996.01]
Riluzole and ALS therapy. [1996]
A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. [1994.03.03]
Well-designed clinical trials possibly related to Rilutek (Riluzole)
Glutamate release inhibition ineffective in levodopa-induced motor complications. [2006.09]
Pentoxifylline in ALS: a double-blind, randomized, multicenter, placebo-controlled trial. [2006.01.10]
Minocycline in amyotrophic lateral sclerosis: a pilot study. [2005.10]
A pilot, double-blind, placebo-controlled trial of indinavir in patients with ALS. [2005.04.12]
Advances in clinical trials for amyotrophic lateral sclerosis. [2005.02]
Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials. [2004.06]
Placebo-controlled phase I/II studies of minocycline in amyotrophic lateral sclerosis. [2004.05.25]
A double-blind randomized clinical trial in amyotrophic lateral sclerosis using lamotrigine: effects on CSF glutamate, aspartate, branched-chain amino acid levels and clinical parameters. [2003.07]
Interferon beta-1a in primary progressive multiple sclerosis. [2003.02.15]
Cerebrospinal fluid filtration in amyotrophic lateral sclerosis. [1999.09]
Use of the repeated cross-over design in assessing bioequivalence: (within and between subjects variability - Schuirmann Confidence Intervals estimation). [1998.04]
Other research related to Rilutek (Riluzole)
Riluzole in psychiatry: a systematic review of the literature. [2008.09]
Hippocampal N-acetylaspartate concentration and response to riluzole in generalized anxiety disorder. [2008.05.01]
An association study of riluzole serum concentration and survival and disease progression in patients with ALS. [2008.05]
Pharmacokinetics of riluzole: evidence for glucuronidation as a major metabolic pathway not associated with UGT1A1 genotype. [2008.04]
Plasma glutamate and glycine levels in patients with amyotrophic lateral sclerosis: the effect of riluzole treatment. [2008.03]
Riluzole and D-amphetamine interactions in humans. [2008.01.01]
An open-label trial of riluzole, a glutamate antagonist, in children with treatment-resistant obsessive-compulsive disorder. [2007.12]
Insulin increases retinal hemorrhage in mild oxygen-induced retinopathy in the rat: inhibition by riluzole. [2007.12]
Evaluation of the systemic use of riluzole in post-traumatic facial nerve regeneration: experimental study in rabbits. [2007.11]
Riluzole metabolism and CYP1A1/2 polymorphisms in patients with ALS. [2007.10]
Impairment of GH secretion in amyotrophic lateral sclerosis is not affected by riluzole treatment. [2007.10]
Riluzole, a glutamate release inhibitor, induces loss of righting reflex, antinociception, and immobility in response to noxious stimulation in mice. [2007.06]
Riluzole and d-amphetamine interactions in humans. [2007.05.18]
Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms. [2007.03.15]
A comparison of the glutamate release inhibition and anti-allodynic effects of gabapentin, lamotrigine, and riluzole in a model of neuropathic pain. [2007.03]
Riluzole and amyotrophic lateral sclerosis survival: a population-based study in southern Italy. [2007.03]
Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). [2007.01.24]
Maintenance of eupnea of in situ and in vivo rats following riluzole: a blocker of persistent sodium channels. [2007.01.15]
Outcome of sporadic amyotrophic lateral sclerosis treated with non-invasive ventilation and riluzole. [2007]
Riluzole promotes cell survival and neurite outgrowth in rat sensory neurones in vitro. [2006.12]
Audit of outcomes in motor neuron disease (MND) patients treated with riluzole. [2006.06]
Riluzole, unlike the AMPA antagonist RPR119990, reduces motor impairment and partially prevents motoneuron death in the wobbler mouse, a model of neurodegenerative disease. [2006.03]
The glutamate release inhibitor riluzole attenuates the formation of conditioned place aversion induced by naloxone in rats undergoing a single morphine exposure. [2006.01.19]
[Strong suspicion of lung toxicity due to riluzole] [2006.01]
Riluzole therapy for motor neurone disease: an early Australian experience (1996-2002). [2006.01]
Alpha-linolenic acid and riluzole treatment confer cerebral protection and improve survival after focal brain ischemia. [2006]
The metabotropic glutamate receptor subtype 5 antagonist MPEP and the Na+ channel blocker riluzole show different neuroprotective profiles in reversing behavioral deficits induced by excitotoxic prefrontal cortex lesions. [2006]
Open-label trial of riluzole in generalized anxiety disorder. [2005.12]
Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. [2005.09.01]
Riluzole improves motor deficits and attenuates loss of striatal neurons in a sequential double lesion rat model of striatonigral degeneration (parkinson variant of multiple system atrophy). [2005.08]
Neuroprotective effect of riluzole in acute noise-induced hearing loss. [2005.07.13]
Glutamate inhibition in MS: the neuroprotective properties of riluzole. [2005.06.15]
High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study. [2005.05]
Effects of riluzole on combined MPTP + 3-nitropropionic acid-induced mild to moderate striatonigral degeneration in mice. [2005.05]
Association between CYP1A2 activity and riluzole clearance in patients with amyotrophic lateral sclerosis. [2005.03]
The ALS/MND prevalence in Sweden estimated by riluzole sales statistics. [2005.03]
An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. [2005.02.15]
Interactions between riluzole and conventional antiepileptic drugs -- a comparison of results obtained in the subthreshold method and isobolographic analysis. [2004.12]
The tolerability of riluzole in the treatment of patients with amyotrophic lateral sclerosis. [2004.11]
Riluzole slows the progression of neuromuscular dysfunction in the wobbler mouse motor neuron disease. [2004.09.03]
Rasagiline alone and in combination with riluzole prolongs survival in an ALS mouse model. [2004.09]
Co-treatment with riluzole and GDNF is necessary for functional recovery after ventral root avulsion injury. [2004.06]
Riluzole restores motor activity in rats with post-traumatic peripheral neuropathy. [2004.03.18]
Riluzole enhances the anti-seizure action of conventional antiepileptic drugs against pentetrazole-induced convulsions in mice. [2004.03]
[Tolerability of riluzole: a review of the literature] [2004.01]
Double-blind comparison of the continued use of antipsychotic treatment versus its discontinuation in remitted manic patients. [2004.01]
Riluzole suppresses experimental autoimmune encephalomyelitis: implications for the treatment of multiple sclerosis. [2003.11.07]
Effect of riluzole (Rilutek) treatment on plasma amino acid percentages in amyotrophic lateral sclerosis patients. [2003.11]
Riluzole serum concentrations in patients with ALS: associations with side effects and symptoms. [2003.10.28]
The use of the potassium channel activator riluzole to test whether potassium channels mediate the capacity of isoflurane to produce immobility. [2003.10]
Riluzole and blood pressure in multiple system atrophy. [2003.08]
An outcome study of riluzole in amyotrophic lateral sclerosis--a population-based study in Ireland, 1996-2000. [2003.04]
Effect of riluzole on MK-801 and amphetamine-induced hyperlocomotion. [2003]
Creatine supplementation and riluzole treatment provide similar beneficial effects in copper, zinc superoxide dismutase (G93A) transgenic mice. [2003]
The effect of the neuroprotective agent riluzole on MRI parameters in primary progressive multiple sclerosis: a pilot study. [2002.12]
Effect of riluzole on cytosolic Ca2+ increase in human osteosarcoma cells. [2002.11]
Riluzole enhances expression of brain-derived neurotrophic factor with consequent proliferation of granule precursor cells in the rat hippocampus. [2002.08]
Molsidomine potentiates the protective activity of GYKI 52466, a non-NMDA antagonist, MK-801, a non-competitive NMDA antagonist, and riluzole against electroconvulsions in mice. [2002.08]
Effect of Riluzole on serum amino acids in patients with amyotrophic lateral sclerosis. [2002.07]
Therapies in amyotrophic lateral sclerosis-beyond riluzole. [2002.06]
[Tolerance of riluzole in a phase IIIb clinical trial] [2002.01]
Riluzole therapy in cervical dystonia. [2002.01]
Neuroprotective effect of riluzole in a primate model of Parkinson's disease: behavioral and histological evidence. [2002.01]
Disease progression in amyotrophic lateral sclerosis. Identifying the cost-utility of riluzole by disease stage. [2002]
Secondary injury mechanisms of spinal cord trauma: a novel therapeutic approach for the management of secondary pathophysiology with the sodium channel blocker riluzole. [2002]
Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). [2002]
Riluzole rescues cochlear sensory cells from acoustic trauma in the guinea-pig. [2002]
Riluzole suppresses post-sigh, but not spontaneous apnoeas during sleep in rats. [2001.11]
|
